Trial Profile

A phase I-II, open-label study of RAD001 [everolimus] in combination with Gleevec [imatinib; ST 1571] in refractory/resistant gastrointestinal stromal tumors.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Jun 2021 Number of treatment arms increased form 1 to 6 by introducing additional dose levels for Imatinib and Everolimus, single-group assignment is changed to sequential assignment. Additional Safety primary end-point is also introduced, thus adding "AR" as the trial focus.
31 May 2012 Additional locations identified as reported by ClinicalTrials.gov.
11 Jan 2011 Primary endpoint identified as (Pharmacokinetic-parameters, Objective-clinical-response) as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com